Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Systemic Lupus Erythematosus
- Enrollment Status: Closed
- Protocol: CA42750
- Drug: OBINUTUZUMAB
- Sponsor: Roche
- Description: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
Clinical Research Institute of Michigan – Shores Rheumatology
Primary Coordinator: Amelia Paliewicz 586-598-3329 X 201
- Indication: Systemic Sclerosis
- Enrollment Status: Open
- Protocol: CVAY736S12201
- Drug: Ianalumab
- Sponsor: Novartis
- Description: A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab in participants with diffuse cutaneous systemic sclerosis
